ABBOTT LABORATORIES — Director's Dealing 2019

Apr 4, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-04-01

Reporting Person: WOODGRIFT RANDEL WILLIAM (Senior Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	42284	Direct
Common shares without par value	2634	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$47	2025-02-19	Common shares (47226)		Direct
Option (right to buy)	$38.40	2026-02-18	Common shares (83333)		Direct
Option (right to buy)	$44.40	2027-02-16	Common shares (53271)		Direct
Option (right to buy)	$59.94	2028-02-15	Common shares (69605)		Direct
Option (right to buy)	$75.90	2029-02-21	Common shares (42009)		Direct

Footnotes

F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 1, 2019.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,742 on February 20, 2016, 15,742 on February 20, 2017, and 15,742 on February 20, 2018.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 27,778 on February 19, 2017, 27,777 on February 19, 2018, and 27,778 on February 19, 2019.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 17,757 and 17,757 became exercisable on February 17, 2018 and February 17, 2019, respectively, and 17,757 becomes exercisable on February 17, 2020.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 23,202 became exercisable on February 16, 2019 and 23,201 and 23,202 becomes exercisable on February 16, 2020 and February 16, 2021, respectively.

F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,003 on February 22, 2020, 14,003 on February 22, 2021, and 14,003 on February 22, 2022.